Phibro Animal Health (NASDAQ:PAHC) Updates FY 2027 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) updated its FY 2027 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.410-3.590 for the period, compared to the consensus estimate of 3.340. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on PAHC shares. Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Citigroup reduced their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Finally, Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Phibro Animal Health presently has an average rating of “Hold” and a consensus price target of $42.50.

Phibro Animal Health Trading Up 0.4%

Shares of Phibro Animal Health stock opened at $36.09 on Thursday. Phibro Animal Health has a 1 year low of $28.25 and a 1 year high of $60.08. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The business has a 50 day moving average price of $33.95 and a 200 day moving average price of $42.44. The company has a market capitalization of $1.46 billion, a P/E ratio of 15.49, a P/E/G ratio of 0.51 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 26th. The company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.14. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The firm had revenue of $396.75 million for the quarter, compared to analysts’ expectations of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. Sell-side analysts anticipate that Phibro Animal Health will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Wednesday, September 2nd. Phibro Animal Health’s dividend payout ratio is 20.60%.

Institutional Trading of Phibro Animal Health

A number of hedge funds have recently bought and sold shares of PAHC. iSAM Funds UK Ltd purchased a new stake in shares of Phibro Animal Health in the third quarter valued at $61,000. EverSource Wealth Advisors LLC boosted its stake in Phibro Animal Health by 7,671.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after buying an additional 2,685 shares during the last quarter. C M Bidwell & Associates Ltd. grew its holdings in Phibro Animal Health by 1,756.5% in the 4th quarter. C M Bidwell & Associates Ltd. now owns 2,135 shares of the company’s stock valued at $80,000 after buying an additional 2,020 shares during the period. Advisory Services Network LLC purchased a new stake in Phibro Animal Health in the 3rd quarter valued at about $96,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Phibro Animal Health by 768.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after acquiring an additional 4,079 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.